These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 17909051)

  • 1. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.
    Loberg RD; Ying C; Craig M; Day LL; Sargent E; Neeley C; Wojno K; Snyder LA; Yan L; Pienta KJ
    Cancer Res; 2007 Oct; 67(19):9417-24. PubMed ID: 17909051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration.
    Loberg RD; Ying C; Craig M; Yan L; Snyder LA; Pienta KJ
    Neoplasia; 2007 Jul; 9(7):556-62. PubMed ID: 17710158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets.
    Schober A; Zernecke A; Liehn EA; von Hundelshausen P; Knarren S; Kuziel WA; Weber C
    Circ Res; 2004 Nov; 95(11):1125-33. PubMed ID: 15528472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation, characterization and biological activity of CCL2 (MCP-1/JE) and CCL12 (MCP-5) specific antibodies.
    Tsui P; Das A; Whitaker B; Tornetta M; Stowell N; Kesavan P; Kaiser E; Lacy ER; Yan L; Snyder LA; Sweet R
    Hum Antibodies; 2007; 16(3-4):117-25. PubMed ID: 18334747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential involvement of monocyte chemoattractant protein (MCP)-1/CCL2 in IL-4-mediated tumor immunity through inducing dendritic cell migration into the draining lymph nodes.
    Wang H; Nemoto-Sasaki Y; Kondo T; Akiyama M; Mukaida N
    Int Immunopharmacol; 2003 May; 3(5):627-42. PubMed ID: 12757733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone.
    Kirk PS; Koreckij T; Nguyen HM; Brown LG; Snyder LA; Vessella RL; Corey E
    Int J Mol Sci; 2013 May; 14(5):10483-96. PubMed ID: 23698775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel recombinant fusion protein encoding a 20-amino acid residue of the third extracellular (E3) domain of CCR2 neutralizes the biological activity of CCL2.
    Izhak L; Wildbaum G; Zohar Y; Anunu R; Klapper L; Elkeles A; Seagal J; Yefenof E; Ayalon-Soffer M; Karin N
    J Immunol; 2009 Jul; 183(1):732-9. PubMed ID: 19535619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.
    Wu JD; Haugk K; Coleman I; Woodke L; Vessella R; Nelson P; Montgomery RB; Ludwig DL; Plymate SR
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6153-60. PubMed ID: 17062692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers.
    Huang B; Lei Z; Zhao J; Gong W; Liu J; Chen Z; Liu Y; Li D; Yuan Y; Zhang GM; Feng ZH
    Cancer Lett; 2007 Jul; 252(1):86-92. PubMed ID: 17257744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model.
    Rozel S; Galbán CJ; Nicolay K; Lee KC; Sud S; Neeley C; Snyder LA; Chenevert TL; Rehemtulla A; Ross BD; Pienta KJ
    J Cell Biochem; 2009 May; 107(1):58-64. PubMed ID: 19259948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.
    Li X; Loberg R; Liao J; Ying C; Snyder LA; Pienta KJ; McCauley LK
    Cancer Res; 2009 Feb; 69(4):1685-92. PubMed ID: 19176388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment.
    Mizutani K; Sud S; McGregor NA; Martinovski G; Rice BT; Craig MJ; Varsos ZS; Roca H; Pienta KJ
    Neoplasia; 2009 Nov; 11(11):1235-42. PubMed ID: 19881959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption.
    Lu Y; Cai Z; Xiao G; Keller ET; Mizokami A; Yao Z; Roodman GD; Zhang J
    Cancer Res; 2007 Apr; 67(8):3646-53. PubMed ID: 17440076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
    Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
    Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
    Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of stromal-epithelial interactions on breast cancer in vitro and in vivo.
    Potter SM; Dwyer RM; Hartmann MC; Khan S; Boyle MP; Curran CE; Kerin MJ
    Breast Cancer Res Treat; 2012 Jan; 131(2):401-11. PubMed ID: 21344235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.
    Zhang J; Lu Y; Pienta KJ
    J Natl Cancer Inst; 2010 Apr; 102(8):522-8. PubMed ID: 20233997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
    Zhao XY; Schneider D; Biroc SL; Parry R; Alicke B; Toy P; Xuan JA; Sakamoto C; Wada K; Schulze M; Müller-Tiemann B; Parry G; Dinter H
    Cancer Res; 2005 Apr; 65(7):2846-53. PubMed ID: 15805286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
    Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM
    Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.